-
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
Study
EGAS50000000387
-
Blood Group Genotypes and Phenotypes in Omani Blood Donors and Its Links With Susceptibility to Malaria
Study
phs003694
-
Distinct immune cell infiltration patterns in PDAC exhibit divergent immune cell selection and immunosuppressive mechanisms
Study
EGAS50000000726
-
Synovial Fibroblast Gene Expression in Response to Fibronectin Fragment
Study
phs003999
-
Non-neuronal TGF-β–mediated extracellular matrix remodeling drives neurodegeneration in a PSP-Richardson syndrome model
Study
EGAS50000001236
-
Genome-wide cell-free DNA fragmentation in patients with cancer
Study
EGAS00001003611
-
Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma
Study
EGAS00001000845
-
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy
Study
EGAS00001005084
-
Rucaparib in patients presenting a metastatic breast cancer with Homologous Recombination Deficiency, without germline BRCA1/2 mutation, pronostic value of high LOH genomic score and predictive value of HRDetect (microarray)
Study
EGAS00001004755
-
A Single-cell Atlas of Progressive TKI Resistance in Chronic Myeloid Leukemia
Study
EGAS00001005509